본문 바로가기

Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q2
저널
PHARMACEUTICALS15(2) · 2022
피인용
Web of Science 6Scopus 8
FWCI (Scopus)
0.68
JCR IF
JCR 2021 5.215
ISSN
1424-8247

저자

  1. Park, Sang-Woo제1저자Chonnam Natl Univ Hosp, Gwangju 61469, South Korea
  2. 이지웅Pusan Natl Univ Hosp, Busan 49241, South Korea
  3. Kook, Michael S.교신저자Univ Ulsan, Asan Med Ctr, Dept Ophthalmol, Coll Med, Seoul 05505, South Korea

초록

© 2022 by the authors. Licensee MDPI, Basel, Switzerland.To compare the efficacy, patient-reported satisfaction, and safety of preservative-free (PF)-tafluprost, PF-dorzolamide/timolol and preservative-containing (P)-latanoprost in Korean glaucoma patients with ocular surface disease (OSD). In a multicenter, prospective, interventional, non-randomized, controlled 12-week trial, 107 eligible patients received PF-tafluprost (n = 37), PF-dor-zolamide/timolol (n = 34), or P-latanoprost eye drops (n = 36). Outcomes included changes from baseline in OSD Index (OSDI) scores (primary endpoint), intraocular pressure (IOP), and patient-reported treatment satisfaction, and safety at 12 weeks. At 12 weeks, the mean total OSDI and sub-domain (dry eye symptoms, visual-related function, environmental triggers) scores significantly improved from baseline with PF-tafluprost and PF-dorzolamide/timolol, but not with P-latano-prost. Significantly more PF-tafluprost than P-latanoprost recipients reported ‘highly improved/im-proved’ satisfaction (no significant difference between PF-dorzolamide/timolol and P-latanoprost). IOP changes were comparable among all three treatment groups. No new safety concerns were ob-served. PF-tafluprost and PF-dorzolamide/timolol showed statistically and clinically significant re-ductions in OSDI compared with P-latanoprost in Korean glaucoma patients with OSD.

키워드

Dorzolamide/timololGlaucomaOcular surface diseaseP-latanoprostPreservative-freeTafluprostQUALITY-OF-LIFEVISUAL-FIELD LOSSDRY EYE DISEASEBENZALKONIUM CHLORIDELONGITUDINAL CHANGESPREVALENCEMEDICATIONSIMPACTSYMPTOMSTOXICITY

식별자

Scopus EID
2-s2.0-85124537851
WoS UID
000826768400002